8 results on '"Juan Churruca Sarasqueta"'
Search Results
2. Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study
- Author
-
Ane Abad-motos, Jesús Troya, Eva Jiménez, Mario Fontán-Vela, Jorge Valencia, Ines Fernandez-Jimenez, Elena Alba Álvaro-Alonso, Elsa Izquierdo-García, Andrea Lazaro Cebas, Elisa Gallego Ruiz-Elvira, Ana Josefa Tebar-Martinez, Belén Garcia-Marina, Gabriela Peña-Lillo, Laura Macaya, Mario Pérez-Butragueño, Blanca Herrero Mendoza, Natividad Plazas Andreu, Liliana Vázquez Bol, Sandra María Gadin López, Álvaro Martínez Alcalá, Sonia Pérez Gonzalez, Amalia Martínez de la Gándara, Alejandro Zuazua Gonzalez, Javier Montoya Adarraga, Miguel Ángel Lara Álvarez, Enrique Calvo Aranda, Rosa M Lorente Ramos, María Alcantud, Roberto Alcázar Arroyo, Verónica Suberviola Sánchez-Caballero, Ariela Candelario Cáceres, Juan Churruca Sarasqueta, Juan Torres Macho, Ismael Escobar Rodríguez, Raquel Ruíz Páez, Alberto Esquivel López, Pablo de la Cueva Dobao, Natalia Blanca López, José García Hinojosa, Cristina Sevillano Collantes, Alfonso Camacho Aroca, Tamar Talaván Zañón, María Ángeles Sánchez Úriz, Carlos Bibiano Guillén, Miguel Ángel López Arenas, Margarita Gimeno Arández, and Francisco Javier Quintero Gutiérrez del Álamo
- Subjects
Medicine - Abstract
Objectives To describe demographic, clinical, radiological and laboratory characteristics, as well as outcomes, of patients admitted for COVID-19 in a secondary hospital.Design and setting Retrospective case series of sequentially hospitalised patients with confirmed SARS-CoV-2, at Infanta Leonor University Hospital (ILUH) in Madrid, Spain.Participants All patients attended at ILUH testing positive to reverse transcriptase-PCR on nasopharyngeal swabs and diagnosed with COVID-19 between 1 March 2020 and 28 May 2020.Results A total of 1549 COVID-19 cases were included (median age 69 years (IQR 55.0–81.0), 57.5% men). 78.2% had at least one underlying comorbidity, the most frequent was hypertension (55.8%). Most frequent symptoms at presentation were fever (75.3%), cough (65.7%) and dyspnoea (58.1%). 81 (5.8%) patients were admitted to the intensive care unit (ICU) (median age 62 years (IQR 51–71); 74.1% men; median length of stay 9 days (IQR 5–19)) 82.7% of them needed invasive ventilation support. 1393 patients had an outcome at the end of the study period (case fatality ratio: 21.2% (296/1393)). The independent factors associated with fatality (OR; 95% CI): age (1.07; 1.06 to 1.09), male sex (2.86; 1.85 to 4.50), neurological disease (1.93; 1.19 to 3.13), chronic kidney disease (2.83; 1.40 to 5.71) and neoplasia (4.29; 2.40 to 7.67). The percentage of hospital beds occupied with COVID-19 almost doubled (702/361), with the number of patients in ICU quadrupling its capacity (32/8). Median length of stay was 9 days (IQR 6–14).Conclusions This study provides clinical characteristics, complications and outcomes of patients with COVID-19 admitted to a European secondary hospital. Fatal outcomes were similar to those reported by hospitals with a higher level of complexity.
- Published
- 2020
- Full Text
- View/download PDF
3. Comprehensive Geriatric Assessment Is a Useful Tool for Predicting the Outcome of Elderly Patients with Hematologic Malignancies in Real Life
- Author
-
Isabel González-gascón-y-Marín, Sara Martínez-Flores, Elena Landete, Elena Baeza-Monedero, María Ángeles Foncillas, Paula Fernández-Montalbán, Carolina Cecilia Muñoz-Novas, Maria Stefania Infante, Karen Marín-Mori, Juan Churruca Sarasqueta, Laura Sánchez-Paz, Victoria Ramos-de-Ascanio, Fátima Brañas, and José Ángel Hernández-Rivas
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
4. Hepatitis fulminante en paciente con amiloidosis primaria con respuesta hematológica completa
- Author
-
Ileana Gefaell-Larrondo, David Roldán-Cortés, Juan Churruca-Sarasqueta, and Ángel Torralba-Morón
- Abstract
La amiloidosis primaria es una enfermedad multisistémica debida al mal plegamiento de proteínas kappa o lambda. El pronóstico es infausto y el tratamiento emplea quimioterapia. La afectación hepática se describe en el 70% de las autopsias de pacientes con amiloidosis sistémica y se asocia a peor pronóstico. Presentamos el caso de un varón de 41 años de edad que debuta con edemas en miembros inferiores y bolsa escrotal y síndrome nefrótico clínico y bioquímico. La biopsia renal es compatible con una amiloidosis primaria. Inicia tratamiento quimioterápico logrando respuesta hematológica completa, pero, a pesar de ello, sufre un fallo hepático fulminante de origen colestásico, y fallece.
- Published
- 2022
5. Is coagulation-protein consumption upon admission linked to COVID-19 severity and mortality?
- Author
-
Francisco C. Ceballos, Pablo Ryan, Rafael Blancas Gómez-Casero, María Martin-Vicente, Erick Joan Vidal-Alcántara, Felipe Peréz-García, Sofía Bartolome, Juan Churruca-Sarasqueta, Ana Virseda-Berdices, Oscar Martínez-González, Oscar Brochado-Kith, Marta Rava, Carolina Vilches-Medkouri, Natalia Blanca-López, Ignacio Ramirez Martinez-Acitores, Patricia Moreira-Escriche, Carmen De Juan, Salvador Resino, Amanda Fernández-Rodríguez, and María Ángeles Jiménez-Sousa
- Subjects
medicine.medical_specialty ,Factor XII ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Antithrombin ,Disease ,Factor XIII ,Asymptomatic ,Gastroenterology ,Coagulation ,Internal medicine ,medicine ,medicine.symptom ,business ,Survival analysis ,medicine.drug - Abstract
The link between coagulation system disorders and COVID-19 has not yet been fully elucidated. With the aim of evaluating the association of several coagulation proteins with COVID-19 severity and mortality, we performed a cross-sectional study in 134 patients classified according to the highest disease severity reached during the disease. We found higher levels of antithrombin, prothrombin, factor XI, factor XII and factor XIII in asymptomatic/mild and moderate COVID-19 patients than healthy individuals. Interestingly, decreased levels of antithrombin, factor XI, XII and XIII were observed in those patients who eventually developed severe illness. Additionally, survival models showed us that patients with lower levels of these coagulation proteins had an increased risk of death. In conclusion, COVID-19 provokes early increments of some specific coagulation proteins in most patients. However, lower levels of these proteins at diagnosis might “paradoxically” imply a higher risk of progression to severe disease and COVID-19-related mortality.
- Published
- 2021
6. Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality?
- Author
-
Amanda Fernández-Rodríguez, Sofía Bartolomé, Oscar Brochado-Kith, Rafael Blancas, Salvador Resino, Ana Virseda-Berdices, Juan Churruca-Sarasqueta, Pablo Ryan, Patricia Moreira-Escriche, Ignacio Ramirez Martinez-Acitores, Carolina Vilches-Medkouri, María Ángeles Jiménez-Sousa, Marta Rava, Natalia Blanca-López, Erick Joan Vidal-Alcántara, Francisco C. Ceballos, María Martín-Vicente, Carmen De Juan, Oscar Martínez-González, Felipe Pérez-García, and Instituto de Salud Carlos III
- Subjects
Medicine (General) ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,coagulation factors ,Gastroenterology ,Asymptomatic ,R5-920 ,Internal medicine ,medicine ,Mortality ,Survival analysis ,SARS ,Factor XII ,business.industry ,SARS-CoV-2 ,Antithrombin ,Coagulation factors ,COVID-19 ,General Medicine ,Brief Research Report ,Factor XIII ,mortality ,Increased risk ,nervous system ,Coagulation ,Medicine ,medicine.symptom ,business ,medicine.drug - Abstract
Background: The link between coagulation system disorders and COVID-19 has not yet been fully elucidated. Aim: Evaluating the association of non-previously reported coagulation proteins with COVID-19 severity and mortality. Design: Cross-sectional study of 134 COVID-19 patients recruited at admission and classified according to the highest COVID-19 severity reached (asymptomatic/mild, moderate, or severe) and 16 healthy control individuals. Methods: Coagulation proteins levels (antithrombin, prothrombin, factor_XI, factor_XII, and factor_XIII) and CRP were measured in plasma by the ProcartaPlex Panel (Invitrogen) multiplex immunoassay upon diagnosis. Results: We found higher levels of antithrombin, prothrombin, factor XI, factor XII, and factor XIII in asymptomatic/mild and moderate COVID-19 patients compared to healthy individuals. Interestingly, decreased levels of antithrombin and factors XI, XII, and XIII were observed in those patients who eventually developed severe illness. Additionally, survival models showed us that patients with lower levels of these coagulation proteins had an increased risk of death. Conclusion: COVID-19 provokes early increments of some specific coagulation proteins in most patients. However, lower levels of these proteins at diagnosis might "paradoxically" imply a higher risk of progression to severe disease and COVID-19-related mortality. This study was supported by grants from Instituto de Salud Carlos III [ISCIII; Grant Number COV20/1144 (MPY224/20) to AF-R/MJ-S]. AF-R, MJ-S, and MR are Miguel Servet researchers supported and funded by ISCIII (Grant Numbers: CP14CIII/00010 to AF-R, CP17CIII/00007 to MJ-S, and CP19CIII/00002 to MR). Sí
- Published
- 2021
7. Blood transfusion activity in a general hospital during the COVID-19 pandemic
- Author
-
Mercedes Duffort-Falco, Juan Churruca-Sarasqueta, Isabel González-Gascón y Marín, Elena Landete-Hernández, Begoña Bueno-García, Carolina Muñoz-Novas, Karen Marín-Mori, María Stefania Infante, Jose Angel Hernandez-Rivas, and María Ángeles Foncillas-García
- Subjects
medicine.medical_specialty ,Blood transfusion ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Hospitals, General ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Pandemic ,medicine ,Humans ,Platelet ,Blood Transfusion ,business.industry ,Outbreak ,COVID-19 ,Retrospective cohort study ,Hematology ,General Medicine ,Intensive care unit ,Red blood cell ,medicine.anatomical_structure ,Spain ,Emergency medicine ,business ,030215 immunology - Abstract
BACKGROUND: The COVID-19 outbreak has affected almost all hospital departments, including transfusion services. However, the demand for transfusions in a general hospital designated to deal with COVID-19 patients has not been analysed before. STUDY DESIGN AND METHODS: A retrospective study was conducted to evaluate blood transfusion practices from 15 March to 14 April 2020 at Hospital Universitario Infanta Leonor (Madrid, Spain). During this month, with few exceptions, the hospital became a 'COVID-19' centre. In addition, transfusion rates during this time frame and the same period over the last 4 years were compared. RESULTS: From 15 March to 14 April 2020, only 254 blood components were transfused, resulting in a 49·3% reduction over the previous year. Interestingly, in critically ill patients, the red blood cell (RBC) transfusion/bed ratio significantly decreased during this period (0·92) compared to the same ratio over the past 4 years (2·70) (P = 0·02). Of note, 106 blood components (95 RBC; 11 platelet concentrates) were transfused to only 36 out of 1348 COVID-19 patients (2·7%). The main reason for RBC transfusion in COVID-19 patients was a previous underlying disease (44%) followed by bleeding (25%) and inflammatory anaemia (25%). CONCLUSION: This is the first study to report a decrease in blood transfusions during the COVID-19 pandemic in a general hospital and especially in the intensive care unit. The results of this study suggest that COVID-19 does not generally induce transfusion requiring anaemia, being the main causes for transfusion in these patients underlying conditions or bleeding.
- Published
- 2020
8. Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality?
- Author
-
Francisco C. Ceballos, Pablo Ryan, Rafael Blancas, María Martin-Vicente, Erick Joan Vidal-Alcántara, Felipe Peréz-García, Sofía Bartolomé, Juan Churruca-Sarasqueta, Ana Virseda-Berdices, Oscar Martínez-González, Oscar Brochado-Kith, Marta Rava, Carolina Vilches-Medkouri, Natalia Blanca-López, Ignacio Ramirez Martinez-Acitores, Patricia Moreira-Escriche, Carmen De Juan, Salvador Resino, Amanda Fernández-Rodríguez, and María Ángeles Jiménez-Sousa
- Subjects
SARS-CoV-2 ,coagulation factors ,COVID-19 ,mortality ,SARS ,Medicine (General) ,R5-920 - Abstract
Background: The link between coagulation system disorders and COVID-19 has not yet been fully elucidated.Aim: Evaluating the association of non-previously reported coagulation proteins with COVID-19 severity and mortality.Design: Cross-sectional study of 134 COVID-19 patients recruited at admission and classified according to the highest COVID-19 severity reached (asymptomatic/mild, moderate, or severe) and 16 healthy control individuals.Methods: Coagulation proteins levels (antithrombin, prothrombin, factor_XI, factor_XII, and factor_XIII) and CRP were measured in plasma by the ProcartaPlex Panel (Invitrogen) multiplex immunoassay upon diagnosis.Results: We found higher levels of antithrombin, prothrombin, factor XI, factor XII, and factor XIII in asymptomatic/mild and moderate COVID-19 patients compared to healthy individuals. Interestingly, decreased levels of antithrombin and factors XI, XII, and XIII were observed in those patients who eventually developed severe illness. Additionally, survival models showed us that patients with lower levels of these coagulation proteins had an increased risk of death.Conclusion: COVID-19 provokes early increments of some specific coagulation proteins in most patients. However, lower levels of these proteins at diagnosis might “paradoxically” imply a higher risk of progression to severe disease and COVID-19-related mortality.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.